A 2018 study of adults and children who were taking antibiotics and co-administered a probiotic supplement showed a lower risk of Clostridium difficile infections. The study authors concluded ...

Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA® (fecal ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA ...

Therefore, new therapeutic or strategies already available for treatment of CDI have two goals: eradicating the infection, despite the continuation of concomitant therapy, and reducing the ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

NICE have found that the evidence supporting FMT for recurrent Clostridium difficile infection is sufficient for the procedure to be carried out. However, it is only considered when patients have ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed.

LPOXY’s plan is to take Sidiprev into a phase 2 study in hospitalized patients with Clostridioides difficile infection. Known as one of the superbugs that resists most antibiotics, C.